Our Take
Antibiotic stewardship alone has been the policy anchor for 20 years; this work argues it was never sufficient, and public health budgets in high-income countries have been misallocated.
Why it matters
Antimicrobial resistance is projected to kill 39 million people in the next 25 years. If inequality and sanitation are the primary drivers, then drug rationing in wealthy countries does nothing to slow resistance in the places where it spreads fastest.
Do this week
Public health officers: audit your AMR strategy document against the 210 pathogen-specific traits and socioeconomic indicators flagged in this study before your next budget cycle, so you can reallocate toward sanitation and nutrition interventions in high-risk regions.
King's College London researchers analyzed 45,000 bacterial genomes from 127 countries
The team examined 16 bacterial species classified by the World Health Organization as critical priority pathogens, including Klebsiella, Acinetobacter, and Escherichia coli. They cross-referenced resistance genes in these species against more than 1,000 environmental, health, and socioeconomic indicators—poverty, climate, healthcare infrastructure, mortality rates, and social determinants of health—to model which resistance traits are likely to spread through 2050.
The analysis identified 210 antimicrobial resistance traits with the strongest correlation to future prevalence. Of those, 32 were flagged as critical threats. The research, published in Cell Genomics, found that socioeconomic disparities emerged as the primary association for these 32 critical traits, followed by mortality and antibiotic consumption (company-reported via King's College London).
Current AMR policy has treated antibiotic stewardship as the primary lever
Governments and hospital systems across the developed world have invested heavily in antibiotic use reduction—protocols, audits, prescribing limits, and surveillance. That approach assumes that less consumption directly translates to less resistance. This study contradicts that model. Mortality, inequality, sanitation, and crowding show stronger statistical association with future resistance prevalence than consumption patterns alone.
The implication is direct: reducing antibiotic use in Denmark or the United States will not meaningfully slow resistance in regions where sewage systems are inadequate, nutrition is poor, and populations are densely housed. Resistance spreads through poverty-driven vectors—healthcare gaps, water contamination, malnutrition that weakens immune response—not primarily through overprescribing in wealthy countries.
Antimicrobial resistance is projected to claim more than 39 million lives over the next 25 years (The Lancet, September 2025). If the structural drivers are inequality and living conditions, then public health strategy must follow the money toward sanitation, nutrition, and health equity in high-risk areas, not just toward stewardship campaigns.
Use this data to reset AMR investment priorities
The study provides a roadmap: 210 resistance traits linked to specific socioeconomic and environmental factors offer a granular basis for targeted surveillance and intervention. Rather than generic antibiotic stewardship, governments and NGOs can now model which pathogens and resistance profiles will pose the highest threat in specific regions and what structural changes will most directly prevent them.
Senior author Tania Dottorini noted: "Reducing antibiotic use alone won't be enough. Tackling AMR requires structural interventions on inequality, sanitation, nutrition and health equity alongside stewardship." For policy makers, this means reframing AMR as a structural inequality problem, not a prescribing problem. For funders, it means shifting investment away from hospital-level stewardship audits in high-income countries and toward water, sanitation, nutrition, and primary care infrastructure in regions where resistance prevalence is rising fastest.